Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination involves **cyclophosphamide**, a nitrogen mustard alkylating agent used in chemotherapy; **bismuth subgallate**, a compound with hemostatic and wound healing properties; **prednisone**, a corticosteroid; **etoposide**, a topoisomerase inhibitor; and **procarbazine**, an alkylating agent. Cyclophosphamide is used in treating cancers and autoimmune diseases, while prednisone is used for its anti-inflammatory effects. Etoposide and procarbazine are primarily used in cancer treatment. Bismuth subgallate is not commonly used in cancer treatment but has been explored for surgical applications due to its hemostatic properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide + bismuth subgallate + prednisone + etoposide + procarbazine.